INO stock is putting vaccine news front and center -- in place of strong fundamentals. If you decide to take a chance, be aware -- it's a specuative on The post Inovio Stock Is a Sideshow, Not a Serio
These are the top stocks to buy based on the 2020 U.S. presidential election, with new stock picks updated daily from the sharpest investing minds in the business.
Even a vaccine that's 50% effective with some side effects would be a game changer. The Trump Administration is throwing billions into that hope and investors are seeing big profits.
Reports of an early approval for AstraZeneca's COVID-19 vaccine are sending these three stocks lower today.

3 Coronavirus Stocks to Go on the Defensive

06:05am, Monday, 24'th Aug 2020
The pandemic shows no signs of slowing, it's time to use any signs of weakness in coronavirus stocks as a buying opportunity. The post 3 Coronavirus Stocks to Go on the Defensive appeared first on In
Here's exactly how they could realistically pull it off.

Inovio Becomes a Covid-19 Longshot

11:11am, Thursday, 20'th Aug 2020
No one knows which of the many vaccine candidates will be safe and effective, but Inovio's unique approach has left it without a major manufacturing contract. The post Inovio Becomes a Covid-19 Longs
Encouraging preliminary results for its Covid-19 vaccine and its budding HPV solutions make INO stock a great bet at this stage. The post Inovio Pharmaceuticals Stock Isn’t Just a Solid Covid-19 Pl

COVID-19: The Real Results Are A Long Way Away

03:47pm, Wednesday, 19'th Aug 2020
Hope for a successful vaccine by the winter is fueling trials at a record pace.
CureVac (NASDAQ: CVAC) held its initial public offering (IPO) on the Nasdaq stock exchange last week. CureVac expected the IPO share price would be between $14 and $16. Here's what you'll want to k
With more competition in the vaccine race, INO stock lost much of its sheen. But don’t rule out Inovio Pharmaceuticals because it has critical advantages that others lack.
This stock has skyrocketed this year as part of the COVID-19 vaccine development race, but will the momentum continue?
Inovio Pharmaceuticals (NASDAQ: INO) has enjoyed a remarkable year so far by any standard. Inovio's shares have skyrocketed close to 350%. A lot could happen to derail the company's fast track to su
This stock has skyrocketed this year as part of the COVID-19 vaccine development race, but will the momentum continue?
The small biotech has some big hurdles to jump over the next few months.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE